BioMarin Pharmaceutical | BMRN - Current Assets


BioMarin Pharmaceutical reported $3.95B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Bayer EUR 32.88B 873M Sep/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025